Methods and antibodies for modulation of immunoresponse
AssigneeAscendo Biotechnology, Inc.
InventorsYen-Ta Lu, Chia-Ming Chang, Tsai-Yin Wei, I-Fang Tsai, Ling-Chiao Wu
Life of this patent
Estimating the term…
Abstract
A method for reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a composition to a subject in need of such treatments, wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.
Claims13
A method of treating a disease associated with immune suppression, comprising administering a composition to a subject in need thereof, inhibiting PD-L1 expression, and reversing immune suppression or immune exhaustion in the subject, thereby treating a disease associated with immune suppression, wherein the composition comprises an antibody or antigen-binding portion thereof comprising:
- (i) a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:1, H-CDR2 having the sequence of SEQ ID NO:3, and H-CDR3 having the sequence of SEQ ID NO:5;
- or a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:2, H-CDR2 having the sequence of SEQ ID NO:4, and H-CDR3 having the sequence of SEQ ID NO:6;
- and
- (ii) a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:7, L-CDR2 having the sequence of SEQ ID NO:9, and L-CDR3 having the sequence of SEQ ID NO:11;
- or a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:8, L-CDR2 having the sequence of SEQ ID NO:10, and L-CDR3 having the sequence of SEQ ID NO:12.
A method for reversing immune suppression or immune exhaustion in a subject in need thereof, comprising:
- administering an antibody or an antigen-binding portion thereof, thereby reversing immune suppression or immune exhaustion in the subject, wherein the antibody or antigen-binding portion thereof comprises:
- (i) a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:1, H-CDR2 having the sequence of SEQ ID NO:3, and H-CDR3 having the sequence of SEQ ID NO:5;
- or a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:2, H-CDR2 having the sequence of SEQ ID NO:4, and H-CDR3 having the sequence of SEQ ID NO:6;
- and
- (ii) a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:7, L-CDR2 having the sequence of SEQ ID NO:9, and L-CDR3 having the sequence of SEQ ID NO:11;
- or a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:8, L-CDR2 having the sequence of SEQ ID NO:10, and L-CDR3 having the sequence of SEQ ID NO:12.
Dependencies are inferred from the claim text.